{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T10:42:45Z","timestamp":1777891365365,"version":"3.51.4"},"posted":{"date-parts":[[2022,7,11]]},"group-title":"Bioinformatics","reference-count":31,"publisher":"openRxiv","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2022,7,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>\n                  Diseases caused by new viruses costs thousands if not millions of human lives and trillions of dollars in damage to the global economy. Despite the rapid development of vaccines for SARS-CoV-2, the lack of small molecule antiviral drugs that work against multiple viral families (broad-spectrum antivirals; BSAs) has left the entire world\u2019s human population vulnerable to the infection between the beginning of the outbreak and the widespread availability of vaccines. Developing BSAs is an attractive, yet challenging, approach that could prevent the next, inevitable, viral outbreak from becoming a global catastrophe. To explore whether historical medicinal chemistry efforts suggest the possibility of discovering novel BSAs, we (i) identified, collected, curated, and integrated all chemical bioactivity data available in ChEMBL for molecules tested in respective assays for 13 emerging viruses that, based on published literature, hold the greatest potential threat to global human health; (ii) identified and solved the challenges related to data annotation accuracy including assay description ambiguity, missing cell or target information, and incorrect BioAssay Ontology (BAO) annotations; (iii) developed a highly curated and thoroughly annotated database of compounds tested in both phenotypic (21,392 entries) and target-based (11,123 entries) assays for these viruses; and (iv) identified a subset of compounds showing BSA activity. For the latter task, we eliminated inconclusive and annotated duplicative entries by checking the concordance between multiple assay results and identified eight compounds active against 3-4 viruses from the phenotypic data, 16 compounds active against two viruses from the target-based data, and 35 compounds active in at least one phenotypic and one target-based assay. The pilot version of our SMACC (Small Molecule Antiviral Compound Collection) database contains over 32,500 entries for 13 viruses. Our analysis indicates that previous research yielded very small number of BSA compounds. We posit that focused and coordinated efforts strategically targeting the discovery of such agents must be established and maintained going forward. The SMACC database publicly available at\n                  <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/smacc.mml.unc.edu\">https:\/\/smacc.mml.unc.edu<\/jats:ext-link>\n                  may serve as a reference for virologists and medicinal chemists working on the development of novel BSA agents in preparation for future viral outbreaks.\n                <\/jats:p>","DOI":"10.1101\/2022.07.09.499397","type":"posted-content","created":{"date-parts":[[2022,7,11]],"date-time":"2022-07-11T12:00:43Z","timestamp":1657540843000},"source":"Crossref","is-referenced-by-count":4,"title":["Small Molecule Antiviral Compound Collection (SMACC): a database to support the discovery of broad-spectrum antiviral drug molecules"],"prefix":"10.64898","author":[{"given":"Holli-Joi","family":"Martin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cleber C.","family":"Melo-Filho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Korn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3580-380X","authenticated-orcid":false,"given":"Richard T.","family":"Eastman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ganesha","family":"Rai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anton","family":"Simeonov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexey V.","family":"Zakharov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4616-7036","authenticated-orcid":false,"given":"Eugene","family":"Muratov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Tropsha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"key":"2022071401200535000_2022.07.09.499397v1.1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1701410114"},{"key":"2022071401200535000_2022.07.09.499397v1.2","first-page":"1","article-title":"Enhanced taxonomy annotation of antiviral activity data from ChEMBL","volume":"2019","year":"2019","journal-title":"Database"},{"key":"2022071401200535000_2022.07.09.499397v1.3","doi-asserted-by":"crossref","first-page":"105360","DOI":"10.1016\/j.antiviral.2022.105360","article-title":"Conserved coronavirus proteins as targets of broad-spectrum antivirals","volume":"204","year":"2022","journal-title":"Antiviral Research"},{"key":"2022071401200535000_2022.07.09.499397v1.4","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00102-15"},{"key":"2022071401200535000_2022.07.09.499397v1.5","unstructured":"Bobrowski, T. et al. Learning from history: do not flatten the curve of antiviral research! Drug Discovery Today 00, 1\u201310 (2020)."},{"key":"2022071401200535000_2022.07.09.499397v1.6","first-page":"1586","article-title":"An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19","volume":"374","year":"2021","journal-title":"Science (1979)"},{"key":"2022071401200535000_2022.07.09.499397v1.7","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.coviro.2011.12.004","article-title":"Metagenomics and future perspectives in virus discovery","volume":"2","year":"2012","journal-title":"Current Opinion in Virology"},{"key":"2022071401200535000_2022.07.09.499397v1.8","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkw1074"},{"key":"2022071401200535000_2022.07.09.499397v1.9","doi-asserted-by":"publisher","DOI":"10.1021\/ci100176x"},{"key":"2022071401200535000_2022.07.09.499397v1.10","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jcim.6b00129"},{"key":"2022071401200535000_2022.07.09.499397v1.11","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/nchembio.1881","article-title":"Curation of chemogenomics data","volume":"11","year":"2015","journal-title":"Nature Chemical Biology"},{"key":"2022071401200535000_2022.07.09.499397v1.12","doi-asserted-by":"crossref","unstructured":"Berthold, M. R. et al. KNIME: The Konstanz Information Miner. in Studies in Classification, Data Analysis, and Knowledge Organization (GfKL 2007) (Springer, 2007).","DOI":"10.1007\/978-3-540-78246-9_38"},{"key":"2022071401200535000_2022.07.09.499397v1.13","unstructured":"The BioAssay Ontology (BAO). http:\/\/bioassayontology.org\/ (2022)."},{"key":"2022071401200535000_2022.07.09.499397v1.14","doi-asserted-by":"publisher","DOI":"10.1007\/s10822-015-9860-5"},{"key":"2022071401200535000_2022.07.09.499397v1.15","unstructured":"ChEMBL Compound Curation Pipeline. http:\/\/chembl.blogspot.com\/2020\/02\/chembl-compound-curation-pipeline.html."},{"key":"2022071401200535000_2022.07.09.499397v1.16","doi-asserted-by":"publisher","DOI":"10.1007\/s10822-015-9860-5"},{"key":"2022071401200535000_2022.07.09.499397v1.17","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2025866118"},{"key":"2022071401200535000_2022.07.09.499397v1.18","doi-asserted-by":"crossref","unstructured":"Park, J.-G. et al. Identification and Characterization of Novel Compounds with Broad-Spectrum Antiviral Activity against Influenza A and B Viruses. Journal of Virology 94, (2020).","DOI":"10.1128\/JVI.02149-19"},{"key":"2022071401200535000_2022.07.09.499397v1.19","doi-asserted-by":"crossref","first-page":"964","DOI":"10.3390\/v11100964","article-title":"Novel Antiviral Activities of Obatoclax, Emetine, Niclosamide, Brequinar, and Homoharringtonine","volume":"11","year":"2019","journal-title":"Viruses"},{"key":"2022071401200535000_2022.07.09.499397v1.20","doi-asserted-by":"crossref","first-page":"108982","DOI":"10.1016\/j.biopha.2019.108982","article-title":"Antiviral activity of brequinar against foot-and-mouth disease virus infection in vitro and in vivo","volume":"116","year":"2019","journal-title":"Biomedicine & Pharmacotherapy"},{"key":"2022071401200535000_2022.07.09.499397v1.21","unstructured":"CRISIS2: A Phase 2 Study of the Safety and Antiviral Activity of Brequinar in Non-hospitalized Pts With COVID-19 - Study Results - ClinicalTrials.gov. https:\/\/www.clinicaltrials.gov\/ct2\/show\/results\/NCT04575038?view=results (2022)."},{"key":"2022071401200535000_2022.07.09.499397v1.22","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/s41586-022-04482-x","article-title":"Pyrimidine inhibitors synergize with nucleoside analogues to block SARS-CoV-2","volume":"604","year":"2022","journal-title":"Nature"},{"key":"2022071401200535000_2022.07.09.499397v1.23","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02510-10"},{"key":"2022071401200535000_2022.07.09.499397v1.24","first-page":"8247","article-title":"Brequinar inhibits enterovirus replication by targeting biosynthesis pathway of pyrimidines","volume":"12","year":"2020","journal-title":"American Journal of Translational Research"},{"key":"2022071401200535000_2022.07.09.499397v1.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2018.08.012"},{"key":"2022071401200535000_2022.07.09.499397v1.26","doi-asserted-by":"publisher","DOI":"10.1101\/2020.06.04.135046"},{"key":"2022071401200535000_2022.07.09.499397v1.27","doi-asserted-by":"publisher","DOI":"10.26434\/CHEMRXIV.13289222.V1"},{"key":"2022071401200535000_2022.07.09.499397v1.28","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1093\/bioinformatics\/btaa718","article-title":"COVID-KOP: integrating emerging COVID-19 data with the ROBOKOP database","volume":"37","year":"2021","journal-title":"Bioinformatics"},{"key":"2022071401200535000_2022.07.09.499397v1.29","doi-asserted-by":"crossref","first-page":"2000113","DOI":"10.1002\/minf.202000113","article-title":"QSAR Modeling of SARS-CoV Mpro Inhibitors Identifies Sufugolix, Cenicriviroc, Proglumetacin, and other Drugs as Candidates for Repurposing against SARS-CoV-2","volume":"40","year":"2021","journal-title":"Molecular Informatics"},{"key":"2022071401200535000_2022.07.09.499397v1.30","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.ymthe.2020.12.016","article-title":"Synergistic and Antagonistic Drug Combinations against SARS-CoV-2","volume":"29","year":"2021","journal-title":"Molecular Therapy"},{"key":"2022071401200535000_2022.07.09.499397v1.31","first-page":"4215","article-title":"Genetic Variability of the SARS-CoV-2 Pocketome","volume":"20","year":"2021","journal-title":"Journal of Proteome Research"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2022.07.09.499397","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T03:20:26Z","timestamp":1768447226000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2022.07.09.499397"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,11]]},"references-count":31,"URL":"https:\/\/doi.org\/10.1101\/2022.07.09.499397","relation":{},"subject":[],"published":{"date-parts":[[2022,7,11]]},"subtype":"preprint"}}